Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Published Online: 2021-11-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Christy Osgood•Danielle Krol•Erik Bloomquist•Gwynn Ison•Jennifer J Gao•Joyce Cheng•Julia A Beaver•Laleh Amiri-Kordestani•Melanie Royce•Rajeshwari Sridhara•Richard Pazdur•Shenghui Tang•Suparna B Wedam•Tatiana M Prowell
